<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006722</article-id><article-id pub-id-type="pmc">PMC11861336</article-id><article-id pub-id-type="doi">10.3390/vaccines13020175</article-id><article-id pub-id-type="publisher-id">vaccines-13-00175</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Nirsevimab Prophylaxis for Reduction of Respiratory Syncytial Virus Complications in Hospitalised Infants: The Multi-Centre Study During the 2023&#x02013;2024 Season in Andalusia, Spain (NIRSEGRAND)</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7017-4095</contrib-id><name><surname>Moreno-P&#x000e9;rez</surname><given-names>David</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af1-vaccines-13-00175" ref-type="aff">1</xref><xref rid="af2-vaccines-13-00175" ref-type="aff">2</xref><xref rid="af3-vaccines-13-00175" ref-type="aff">3</xref><xref rid="af4-vaccines-13-00175" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Korobova</surname><given-names>Aleksandra</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af5-vaccines-13-00175" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Croche-Santander</surname><given-names>Francisco de Borja</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af6-vaccines-13-00175" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6333-5786</contrib-id><name><surname>Cord&#x000f3;n-Mart&#x000ed;nez</surname><given-names>Ana</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af7-vaccines-13-00175" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name><surname>D&#x000ed;az-Morales</surname><given-names>Olga</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af8-vaccines-13-00175" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1493-0060</contrib-id><name><surname>Mart&#x000ed;nez-Campos</surname><given-names>Leticia</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af9-vaccines-13-00175" ref-type="aff">9</xref></contrib><contrib contrib-type="author"><name><surname>P&#x000e9;rez-Gonz&#x000e1;lez</surname><given-names>Elena</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af10-vaccines-13-00175" ref-type="aff">10</xref></contrib><contrib contrib-type="author"><name><surname>Mart&#x000ed;nez-Padilla</surname><given-names>Mar&#x000ed;a del Carmen</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af11-vaccines-13-00175" ref-type="aff">11</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7654-961X</contrib-id><name><surname>Santos-P&#x000e9;rez</surname><given-names>Juan Luis</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="af12-vaccines-13-00175" ref-type="aff">12</xref></contrib><contrib contrib-type="author"><name><surname>Brioso-Galiana</surname><given-names>Jaime</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af13-vaccines-13-00175" ref-type="aff">13</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0132-3015</contrib-id><name><surname>S&#x000e1;nchez-C&#x000f3;dez</surname><given-names>Mar&#x000ed;a Isabel</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af14-vaccines-13-00175" ref-type="aff">14</xref></contrib><contrib contrib-type="author"><name><surname>Del Diego-Salas</surname><given-names>Jorge</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af15-vaccines-13-00175" ref-type="aff">15</xref></contrib><contrib contrib-type="author"><name><surname>Rivera-Izquierdo</surname><given-names>Mario</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af16-vaccines-13-00175" ref-type="aff">16</xref><xref rid="af17-vaccines-13-00175" ref-type="aff">17</xref><xref rid="af18-vaccines-13-00175" ref-type="aff">18</xref><xref rid="c1-vaccines-13-00175" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Lorusso</surname><given-names>Nicola</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af19-vaccines-13-00175" ref-type="aff">19</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Yamazaki</surname><given-names>Tatsuya</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-13-00175"><label>1</label>Health and Consumption Department, General Directorate of Public Health and Pharmaceutical Management of Andalusia, 41020 Seville, Spain; <email>dmp.malaga@gmail.com</email></aff><aff id="af2-vaccines-13-00175"><label>2</label>Department of Paediatrics at the Malaga Mother-and-Child Hospital, Hospital Regional Universitario de M&#x000e1;laga, 29011 M&#x000e1;laga, Spain</aff><aff id="af3-vaccines-13-00175"><label>3</label>Multidisciplinary Group for Paediatric Research, Instituto de Investigaci&#x000f3;n Biom&#x000e9;dica de M&#x000e1;laga (IBIMA), University of M&#x000e1;laga, 29010 M&#x000e1;laga, Spain</aff><aff id="af4-vaccines-13-00175"><label>4</label>Faculty of Medicine, University of M&#x000e1;laga, 29071 M&#x000e1;laga, Spain</aff><aff id="af5-vaccines-13-00175"><label>5</label>Service of Preventive Medicine and Public Health, Hospital Universitario San Cecilio, 18016 Granada, Spain; <email>aleksandra.korobova.sspa@juntadeandalucia.es</email></aff><aff id="af6-vaccines-13-00175"><label>6</label>Service of Paediatrics, Hospital Virgen del Roc&#x000ed;o, 41013 Seville, Spain; <email>francisco.croche.sspa@juntadeandalucia.es</email></aff><aff id="af7-vaccines-13-00175"><label>7</label>Service of Paediatrics, Hospital Regional Universitario de M&#x000e1;laga, 29010 M&#x000e1;laga, Spain; <email>anam.cordon.sspa@juntadeandalucia.es</email></aff><aff id="af8-vaccines-13-00175"><label>8</label>Service of Paediatrics, Hospital Universitario Reina Sofia, 14004 C&#x000f3;rdoba, Spain; <email>olga.diaz.sspa@juntadeandalucia.es</email></aff><aff id="af9-vaccines-13-00175"><label>9</label>Service of Paediatric Infectious Diseases, Hospital Materno Infantil Infanta Leonor, Hospital Universitario Torrec&#x000e1;rdenas, 04009 Almer&#x000ed;a, Spain; <email>lmartinezcampos@gmail.com</email></aff><aff id="af10-vaccines-13-00175"><label>10</label>Service of Paediatrics, Hospital Virgen Macarena, 41009 Seville, Spain; <email>elena.perez.g.sspa@juntadeandalucia.es</email></aff><aff id="af11-vaccines-13-00175"><label>11</label>Service of Paediatrics, Hospital Universitario de Ja&#x000e9;n, 23007 Ja&#x000e9;n, Spain; <email>mcmartinezpadilla@hotmail.com</email></aff><aff id="af12-vaccines-13-00175"><label>12</label>Service of Paediatrics, Hospital Universitario Virgen de las Nieves, 18014 Granada, Spain; <email>jlsantosperez@gmail.com</email></aff><aff id="af13-vaccines-13-00175"><label>13</label>Service of Paediatrics, Hospital Universitario Juan Ram&#x000f3;n Jim&#x000e9;nez, 21005 Huelva, Spain; <email>jaime.brioso.galiana@gmail.com</email></aff><aff id="af14-vaccines-13-00175"><label>14</label>Service of Paediatrics, Hospital Universitario Puerta del Mar, 11009 C&#x000e1;diz, Spain; <email>mscodez1990@gmail.com</email></aff><aff id="af15-vaccines-13-00175"><label>15</label>General Directorate of Public Health and Pharmaceutical Regulation, Ministry of Health and Consumer Affairs of the Regional Government of Andalusia, 41020 Seville, Spain; <email>jorgedeldiego@juntadeandalucia.es</email></aff><aff id="af16-vaccines-13-00175"><label>16</label>Department of Preventive Medicine and Public Health, University of Granada, 18016 Granada, Spain</aff><aff id="af17-vaccines-13-00175"><label>17</label>Instituto de Investigaci&#x000f3;n Biosanitaria de Granada (ibs.GRANADA), 18012 Granada, Spain</aff><aff id="af18-vaccines-13-00175"><label>18</label>Centros de Investigaci&#x000f3;n Biom&#x000e9;dica en Red de Epidemiolog&#x000ed;a y Salud P&#x000fa;blica (CIBERESP), 28029 Madrid, Spain</aff><aff id="af19-vaccines-13-00175"><label>19</label>Service of Surveillance and Occupational Health, General Directorate of Public Health and Pharmaceutical Regulation, Ministry of Health and Consumer Affairs of the Regional Government of Andalusia, 41020 Seville, Spain; <email>nicola.lorusso.sspa@juntadeandalucia.es</email></aff><author-notes><corresp id="c1-vaccines-13-00175"><label>*</label>Correspondence: <email>mariorivera@ugr.es</email></corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>13</volume><issue>2</issue><elocation-id>175</elocation-id><history><date date-type="received"><day>05</day><month>1</month><year>2025</year></date><date date-type="rev-recd"><day>10</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>11</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Background: Nirsevimab was indicated in a population level for all infants &#x0003c; 6 months during the 2023&#x02013;2024 season in Andalusia (southern Spain). Our aim was to analyse the effect of nirsevimab in the reduction in complications in infants hospitalised for RSV bronchiolitis. Methods: A retrospective observational cohort study was conducted in nine relevant hospitals from all provinces of Andalusia, a region with over 9 million inhabitants. The study sample included 222 children, divided into two groups: infants administered with nirsevimab for passive immunisation (exposure) and infants not administered with nirsevimab. Clinical outcomes were analysed, including the use of respiratory support, the need for admission to paediatric intensive care unit (PICU), and duration of hospitalisation. Bivariate analyses were performed, and multivariable logistic regression models were designed to calculate adjusted odds ratios (ORa), and Cox regression models to calculate adjusted hazard ratios (HRa). Results: Bivariate analysis showed an association between passive immunisation with nirsevimab and a lower frequency of numerous outcomes. After adjustment for relevant covariates, multivariable models showed that the exposure (nirsevimab) reduced nasal cannula use by 64% (13&#x02013;85%), invasive or non-invasive mechanical ventilation by 48% (1&#x02013;73%), PICU admission by 54% (14&#x02013;75%), length of hospitalisation by 30% (8&#x02013;47%), and length of nasal cannula by 31% (7&#x02013;49%). A higher risk of co-infection was observed in those immunised (aOR = 3.42, 95%CI: 1.52&#x02013;7.68). Conclusions: Passive immunisation with nirsevimab may decrease the severity of RSV bronchiolitis in infants requiring hospitalisation, thus contributing tertiary prevention that extends beyond the prevention of RSV infection.</p></abstract><kwd-group><kwd>respiratory complications</kwd><kwd>disease severity</kwd><kwd>tertiary prevention</kwd><kwd>clinical effectiveness</kwd><kwd>monoclonal antibodies</kwd><kwd>immunisation</kwd><kwd>paediatric</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-13-00175"><title>1. Introduction</title><p>Human respiratory syncytial virus (RSV) is the leading cause of bronchiolitis in infants worldwide [<xref rid="B1-vaccines-13-00175" ref-type="bibr">1</xref>], which can lead to hospitalisation and death [<xref rid="B1-vaccines-13-00175" ref-type="bibr">1</xref>,<xref rid="B2-vaccines-13-00175" ref-type="bibr">2</xref>]. The hospitalisation rate due to RSV is notably higher in infants under one year of age compared to other age groups [<xref rid="B1-vaccines-13-00175" ref-type="bibr">1</xref>,<xref rid="B2-vaccines-13-00175" ref-type="bibr">2</xref>].</p><p>Currently, effective vaccines are available for active immunisation in pregnant women and individuals aged 60 years or older [<xref rid="B3-vaccines-13-00175" ref-type="bibr">3</xref>,<xref rid="B4-vaccines-13-00175" ref-type="bibr">4</xref>]. However, no RSV vaccines are currently approved for paediatric use. In 2022, the European Medicines Agency (and, subsequently, the Spanish Agency for Medicines and Health Products) authorised the use of nirsevimab (Beyfortus), a long-acting recombinant human monoclonal antibody, which has been demonstrated to neutralise both RSV-A and RSV-B strains [<xref rid="B5-vaccines-13-00175" ref-type="bibr">5</xref>]. A single dose of 50 or 100 mg, according to the infant&#x02019;s weight, can provide protection for at least 5 months [<xref rid="B5-vaccines-13-00175" ref-type="bibr">5</xref>]. Clinical trials evaluating the efficacy and safety of nirsevimab have shown favourable outcomes, with adverse reactions categorised as rare according to the MedDRA system organ class [<xref rid="B5-vaccines-13-00175" ref-type="bibr">5</xref>,<xref rid="B6-vaccines-13-00175" ref-type="bibr">6</xref>,<xref rid="B7-vaccines-13-00175" ref-type="bibr">7</xref>]. Spain is among the pioneering countries to implement a systematic passive immunisation programme against RSV using nirsevimab in infants [<xref rid="B8-vaccines-13-00175" ref-type="bibr">8</xref>]. In Andalusia (a region of southern Spain with over 9 million inhabitants), the nirsevimab campaign for the 2023&#x02013;2024 season started on 1 April 2023, and concluded on 31 March 2024, for all infants under 6 months of age [<xref rid="B8-vaccines-13-00175" ref-type="bibr">8</xref>]. After the close of the campaign in Andalusia, the coverage for nirsevimab in children born during the season was 93.3% [<xref rid="B9-vaccines-13-00175" ref-type="bibr">9</xref>].</p><p>As one of the first areas in the world to establish systematic passive immunisation with nirsevimab in infants at a population level with a successful coverage, the assessment of the clinical impact of the measure through observational studies seemed highly recommended. To date, several studies have been published on the effectiveness of nirsevimab in primary prevention (reduction in RSV infection) [<xref rid="B7-vaccines-13-00175" ref-type="bibr">7</xref>,<xref rid="B10-vaccines-13-00175" ref-type="bibr">10</xref>,<xref rid="B11-vaccines-13-00175" ref-type="bibr">11</xref>] or reduction of hospitalisation [<xref rid="B12-vaccines-13-00175" ref-type="bibr">12</xref>,<xref rid="B13-vaccines-13-00175" ref-type="bibr">13</xref>,<xref rid="B14-vaccines-13-00175" ref-type="bibr">14</xref>]. Nevertheless, a scarcity of studies has been published on other outcomes related to disease severity (complications in RSV-hospitalised children, such as length of hospitalisation, use of respiratory support devices, or need for intensive care) which also measures the clinical effectiveness of nirsevimab at a tertiary prevention level.</p><p>The aim of this study was to evaluate the effectiveness of passive immunisation with nirsevimab and associated factors in reducing the severity of the disease in infants (aged &#x0003c; 6 months) hospitalised with RSV bronchiolitis in Andalusia.</p></sec><sec id="sec2-vaccines-13-00175"><title>2. Materials and Methods</title><p>The findings of this study were reported following the strengthening the reporting of observational studies in epidemiology (STROBE) guidelines [<xref rid="B15-vaccines-13-00175" ref-type="bibr">15</xref>].</p><sec id="sec2dot1-vaccines-13-00175"><title>2.1. Study Setting and Design</title><p>The NIRSEGRAND (Nirsevimab-Gravedad-Andaluc&#x000ed;a; Nirsevimab-Severity-Andalusia in Spanish) study is a retrospective, longitudinal, observational cohort study which included infants born on or after 1 April 2023 who were hospitalised due to RSV bronchiolitis in Andalusia. This study included the hospitals with the highest number of hospital admissions and paediatric intensive care unit (PICU) admissions in each of the provinces of Andalusia. Thus, this multicentre study included all admissions of infants aged &#x0003c; 6 months due to RSV during the 2023&#x02013;2024 campaign in 9 hospitals: University Hospital Torrec&#x000e1;rdenas (Almer&#x000ed;a); University Hospital Puerta del Mar (C&#x000e1;diz); University Hospital Reina Sof&#x000ed;a (C&#x000f3;rdoba); University Hospital Virgen de las Nieves (Granada); University Hospital Juan Ram&#x000f3;n Jim&#x000e9;nez (Huelva); University Hospital of Ja&#x000e9;n (Ja&#x000e9;n); University Regional Hospital of M&#x000e1;laga (M&#x000e1;laga); University Hospital Virgen del Roc&#x000ed;o (Sevilla); and University Hospital Virgen Macarena (Sevilla). The observation period extended from 1 October 2023 to 29 February 2024. RSV infection was confirmed by a positive PCR test from a respiratory sample collected within 10 days before or up to 3 days after the date of hospital admission. Additionally, bronchiolitis was defined by clinical signs of lower respiratory tract infection, apnoea, sepsis, or a compatible severe acute respiratory infection presentation.</p></sec><sec id="sec2dot2-vaccines-13-00175"><title>2.2. Sources of Information and Variables</title><p>The data were collected through a search in the clinical documentation services of the 9 hospitals involved in the study. Data were collected from the electronic medical records systems of the Public Healthcare System of Andalusia.</p><p>The exposure was nirsevimab status (previous administration with nirsevimab at least 4 days before hospital admission). Therefore, infants that had received nirsevimab up to 4 days before hospital admission were considered as passively immunised (exposed), and infants that had not received nirsevimab before admission, or that received nirsevimab during the 4 days previous to admission were considered as not immunised (not exposed), given the incubation period of the agent and the time needed to reach protective plasma levels.</p><p>The outcomes analysed were measured in terms of the need for respiratory support (of any type), conventional nasal cannula, high-flow oxygen therapy, mechanical ventilation (invasive or non-invasive), invasive mechanical ventilation, nasogastric tube, intravenous access, antibiotic use, chest imaging tests, co-infection (viral PCRs measured at admission, or any bacterial or viral infection identified through PCR or respiratory culture during hospitalisation), admission to PICU, and mechanical ventilation in PICU. In addition, the duration of outcomes was also collected; total length of hospitalisation, length of respiratory support, length of nasal cannula, length of high-flow oxygen therapy, length of mechanical ventilation, and length of PICU hospitalisation.</p><p>Other variables collected were sex, hospital of origin, age at admission (in days), use of FilmArray in the diagnosis of RSV infection, and baseline diseases at admission.</p><p>Information collected included baseline demographic and clinical data, clinical symptoms, laboratory and radiologic findings, treatment, and patient outcomes, recorded using standardised forms.</p></sec><sec id="sec2dot3-vaccines-13-00175"><title>2.3. Statistical Analysis</title><p>First, descriptive analyses were performed to describe the characteristics of the study sample. Categorical variables were presented as frequencies and percentages, and quantitative variables were presented as means and standard deviations or median and interquartile ranges where appropriate. Shapiro&#x02013;Wilk tests were used to verify the normal distribution of each quantitative variable.</p><p>Second, a bivariate analysis was conducted between the exposure variable (passive immunisation with nirsevimab) and each of the outcome variables. To evaluate associations with categorical outcomes, chi-square or Fisher&#x02019;s exact test was applied depending on data distribution. For quantitative (temporal) outcomes, the Mann&#x02013;Whitney test was used. Subsequently, cumulative incidence (CI) rates and crude risks ratios (cRR) were calculated. The prevention fraction (PF) was used as a measure of vaccine effectiveness (impact of the exposure), calculated using the formula [(RR &#x02212; 1) &#x000d7; 100]. The calculation was restricted to outcomes that demonstrated a protective RR association. Nevertheless, CIs present a weakness, as it assumes that the risk of developing the effect is constant throughout the study period (hospitalisation), which is usually not true.</p><p>Consequently, incidence rates (IR) were also calculated for each outcome as the number of new cases of each outcome during hospitalisation/total time the population was at risk for this outcome during hospitalisation (sum of total length of hospitalisation for patients that did not develop the outcome plus time from admission to outcome development for patients that developed each outcome). Incidence rate ratios were then calculated comparing the IR of the exposure and non-exposure groups and, subsequently, a PF was calculated from this data [(IRR &#x02212; 1) &#x000d7; 100].</p><p>Third, multivariable analyses were performed for categorical dichotomous outcomes. Before applying logistic regression models, the conditions for application were verified. Crude odds ratios (cOR) and adjusted odds ratios (aOR), along with their 95% confidence intervals (95%CI), were estimated. The dependent variable for each model was each outcome, and the independent variable was the exposure (passive immunisation with nirsevimab). Adjusted models included relevant variables as covariates: sex, age (in days) at admission, hospital, and baselines diseases. Adjusted prevention fractions (aPF) were subsequently calculated, using the formula [(1 &#x02212; aOR) &#x000d7; 100]. The calculation was restricted to outcomes that demonstrated a protective adjusted odds ratio (aOR) association.</p><p>Fourth, survival analyses were conducted to assess temporal outcomes (time to the occurrence of relevant clinical events, e.g., time to discharge which is the total length of hospitalisation). We estimated Kaplan&#x02013;Meier curves to assess the cumulative probability of event-free survival over time, comparing the exposed and non-exposed groups. Differences between survival curves were evaluated using log-rank tests. Additionally, multivariable Cox regression models were applied using sex, age (in days) at admission, hospital, and baselines diseases for adjustments. The results were expressed as hazard ratios (HR) and their respective 95%CI. Before applying these models, the proportionality of risks, absence of multicollinearity, and appropriate model specifications were verified, ensuring the validity and reliability of the results obtained. All statistical analyses were performed using R version 4.1.2 and Stata (StataCorp<sup>&#x000ae;</sup> version 15.0, College Station, TX, USA).</p></sec><sec id="sec2dot4-vaccines-13-00175"><title>2.4. Ethical Considerations</title><p>All data used were anonymised and potentially identifiable variables were removed from analyses. This study complied with ethical requirements established by the Declaration of Helsinki on human research. The study was approved by the Biomedical Research Ethics Coordinating Committee of Andalusia (CCEIBA) on 28 June 2024, (registration code 202499907099520).</p></sec></sec><sec sec-type="results" id="sec3-vaccines-13-00175"><title>3. Results</title><sec id="sec3dot1-vaccines-13-00175"><title>3.1. Characteristics of the Sample</title><p>The study sample included 222 infants, 127 (57.2%) exposed and 95 (42.8%) not exposed to nirsevimab administration. <xref rid="vaccines-13-00175-f001" ref-type="fig">Figure 1</xref> shows the flow chart of sample selection.</p><p>The general characteristics of the sample of infants hospitalised due to RSV are summarised in <xref rid="vaccines-13-00175-t001" ref-type="table">Table 1</xref>. Only one infant was hospitalised within the 4 days after receiving nirsevimab and was considered non-exposed. Of the total, 133 (59.9%) were male, with a higher proportion of males in the immunised group compared to the non-immunised group. The hospital with most admissions was UH Virgen del Roc&#x000ed;o, Seville (<italic toggle="yes">n</italic> = 50). More details on hospital characteristics and their reference populations are presented in <xref rid="app1-vaccines-13-00175" ref-type="app">Supplementary Table S1</xref>.</p><p>The median age at admission was 66 days (IQR = 55.0) in the exposed group, and 45 days (IQR = 99.5) in the non-exposed group. The use of the FilmArray<sup>&#x000ae;</sup> diagnostic tool was more frequent in the exposed group (22.1%) than in the non-exposed group (16.8%). Finally, most infants did not present any baseline disease, but 13 (5.9%) infants had underlying conditions, with higher frequency in the exposed group (7.9% vs. 3.2%). The most frequent condition was congenital heart disease (3.2% of the sample).</p></sec><sec id="sec3dot2-vaccines-13-00175"><title>3.2. Bivariate Analysis</title><p><xref rid="vaccines-13-00175-t002" ref-type="table">Table 2</xref> shows the bivariate associations between exposure (passive immunisation with nirsevimab) and the outcomes analysed during hospitalisation. Briefly, previous nirsevimab administration was associated with less frequent use of a nasal cannula, mechanical ventilation, a nasogastric tube, PICU admission, lower total length of hospitalisation, and a higher frequency of co-infections. The specific co-infections identified (mostly viral) are detailed in <xref rid="app1-vaccines-13-00175" ref-type="app">Supplementary Table S2</xref>.</p><p><xref rid="vaccines-13-00175-t003" ref-type="table">Table 3</xref> presents the results of cumulative incidences (CI) stratified by exposure group, crude risk ratios (cRR), and the preventive fraction calculated to measure the potential impact of nirsevimab (clinical effectiveness). Nirsevimab showed protection for several outcomes, including the need for respiratory support, cRR = 0.92 (95%CI: 0.84&#x02013;1.00), PF = 8.4% (95%CI: 0.0&#x02013;16.1%); nasal cannula, cRR = 0.88 (95%CI: 0.79&#x02013;0.98), PF = 12.1% (95%CI: 2.0&#x02013;21.3%); nasogastric tube, cRR = 0.75 (95%CI: 0.56&#x02013;0.99), PF = 25.2% (0.0&#x02013;43.6%); and PICU admission, cRR = 0.65 (95%CI: 0.48&#x02013;0.87), PF = 35.1% (95%CI: 13.1&#x02013;51.5%).</p><p><xref rid="vaccines-13-00175-t004" ref-type="table">Table 4</xref> shows the results on incidence rate ratios. For this analysis, the outcomes associated with passive immunisation with nirsevimab were mechanical ventilation, IRR: 0.43 (95%CI: 0.29&#x02013;0.66), PF = 56.7% (95%CI: 34.1&#x02013;71.5%), and PICU admission, IRR: 0.49 (95%CI: 0.33&#x02013;0.73), PF = 50.8% (95%CI: 27.0&#x02013;66.9%).</p></sec><sec id="sec3dot3-vaccines-13-00175"><title>3.3. Multivariable Analysis of Dichotomous Outcomes</title><p><xref rid="vaccines-13-00175-t005" ref-type="table">Table 5</xref> presents the results of the multivariate logistic regression models. The exposure (passive immunisation with nirsevimab) was associated with less frequency of need for a nasal cannula, aOR = 0.36 (95%CI: 0.15&#x02013;0.87), aPF = 64% (95%CI: 13&#x02013;85%), mechanical ventilation, aOR = 0.52 (95%CI: 0.27&#x02013;0.99), aPF = 48% (95%CI: 1&#x02013;73%), and PICU admission, aOR = 0.46 (95%CI: 0.25&#x02013;0.86), aPF = 54% (95%CI: 14&#x02013;75%). In addition, passive immunisation with nirsevimab was associated with a higher frequency of co-infections during hospitalisation (aOR = 3.42, 95%CI: 1.52&#x02013;7.68).</p></sec><sec id="sec3dot4-vaccines-13-00175"><title>3.4. Survival Analysis for Temporal Outcomes</title><p>The median time from parental detection of symptoms to hospital admission was 4 days (interquartile range, IQR = 3&#x02013;5 days) for both groups (exposed and non-exposed to passive immunisation with nirsevimab) (<italic toggle="yes">p</italic>-value = 0.807 of Mann&#x02013;Whitney test).</p><p><xref rid="vaccines-13-00175-f002" ref-type="fig">Figure 2</xref> shows the Kaplan&#x02013;Meier curves and the results of log-rank tests for survival analysis stratified by exposure group. Infants administered with nirsevimab showed less time of respiratory support (<italic toggle="yes">p</italic> = 0.049), a nasal cannula (<italic toggle="yes">p</italic> = 0.020), and hospitalisation time (time to discharge) (<italic toggle="yes">p</italic> = 0.005).</p><p>The adjusted Cox regression models (<xref rid="vaccines-13-00175-t006" ref-type="table">Table 6</xref>) showed that nirsevimab was associated with a 30% reduction (95%CI: 8&#x02013;47%) in total hospitalisation time and a 31% reduction (95%CI: 7&#x02013;49%) in the length of nasal cannula.</p></sec></sec><sec sec-type="discussion" id="sec4-vaccines-13-00175"><title>4. Discussion</title><p>In this cohort study based on a real-life preventive universal intervention with nirsevimab in infants aged &#x0003c; 6 months conducted in Andalusia (southern Spain) during the 2023&#x02013;2024 season, we showed interesting findings on tertiary prevention. Infants administered with nirsevimab showed less frequent need for a nasal cannula, mechanical ventilation, PICU admission, and a shorter duration of total hospitalisation and nasal cannula use. These data support the idea that nirsevimab is a useful preventive measure beyond prevention of RSV infection or hospitalisation.</p><p>The use of nirsevimab for universal prevention of infants started in 2023, and Spain was one of the first countries to establish this strategy and, consequently, to collect real data on the potential impact of the measure. As so, some regions of Spain published their data, like Galicia [<xref rid="B16-vaccines-13-00175" ref-type="bibr">16</xref>], Valencia, Murcia or Castilla y Le&#x000f3;n [<xref rid="B17-vaccines-13-00175" ref-type="bibr">17</xref>], Madrid [<xref rid="B18-vaccines-13-00175" ref-type="bibr">18</xref>], or Catalonia [<xref rid="B19-vaccines-13-00175" ref-type="bibr">19</xref>] among others. National data pointed to a 74&#x02013;75% reduction in hospitalisations in infants that received nirsevimab [<xref rid="B20-vaccines-13-00175" ref-type="bibr">20</xref>]. At a population level, the incidence of RSV during the 2023&#x02013;2024 campaign in Spain was similar to previous seasons, with lower frequency in infants, with a dramatic decrease in hospitalisation rates for infants aged &#x0003c; 1 year [<xref rid="B21-vaccines-13-00175" ref-type="bibr">21</xref>], probably due to immunisation strategies in several autonomous communities, including the use of nirsevimab. To date, some recent meta-analyses have showed the effectiveness of nirsevimab in the prevention of RSV infection [<xref rid="B10-vaccines-13-00175" ref-type="bibr">10</xref>,<xref rid="B11-vaccines-13-00175" ref-type="bibr">11</xref>] and reduction of hospitalisation rates due to RSV infection [<xref rid="B12-vaccines-13-00175" ref-type="bibr">12</xref>]. Nevertheless, there is a scarcity of results on outcomes during hospitalisation that could also provide relevant evidence on the potential benefits of nirsevimab in the prevention of disease severity. In this line, Ares-G&#x000f3;mez et al. showed an 86.9% (69.1&#x02013;94.2) reduction in lower respiratory tract infections requiring oxygen support [<xref rid="B16-vaccines-13-00175" ref-type="bibr">16</xref>]. Coma et al. showed protection for ICU admission, with an adjusted HR of 0.099 (95%CI: 0.041&#x02013;0.237) [<xref rid="B19-vaccines-13-00175" ref-type="bibr">19</xref>]. A study conducted in the region of Madrid showed a 94.4% (95% CI: 87.3 to 97.5) reduction in ICU admission at 30 days [<xref rid="B18-vaccines-13-00175" ref-type="bibr">18</xref>]. These associations are even stronger than what we showed because both studies [<xref rid="B18-vaccines-13-00175" ref-type="bibr">18</xref>,<xref rid="B19-vaccines-13-00175" ref-type="bibr">19</xref>] compared a population-based cohort of infants, whilst we compared a cohort of infants hospitalised due to RSV (therefore, their risk of ICU admission is much higher than in the general population and differences between groups decreases due to sample selection). A pooled analysis of randomised controlled trials also showed benefits in severe disease development or antibiotic prescription, among other outcomes [<xref rid="B6-vaccines-13-00175" ref-type="bibr">6</xref>]. Recently, a multicentre study conducted in France in infants aged &#x0003c; 1 year showed reduced oxygen supplementation compared to patients not receiving nirsevimab (20.2% vs. 30.6%) and 1-day shorter hospitalisation [<xref rid="B22-vaccines-13-00175" ref-type="bibr">22</xref>], data similar to those observed in our study.</p><p>One of the most surprising findings of this study was the higher frequency of co-infection in infants administered with nirsevimab. This result could be interpreted from several perspectives. Firstly, protection with nirsevimab against RSV infection may increase the risk of other respiratory opportunistic infections but there is no plausible biological mechanism to justify this fact, to the best of our knowledge, according to the current literature. A reason for reduced co-infection in the non-exposed group could be due to difficulty in sampling patients with increased symptoms, but the severity of the symptoms was not collected in this study. Secondly, although some medications reduce the severity of the primary viral disease, they may create a favourable environment for the proliferation of other pathogens, as seen in co-infection studies with viruses such as influenza [<xref rid="B23-vaccines-13-00175" ref-type="bibr">23</xref>]. Thirdly, the immunological status could influence susceptibility to various infections [<xref rid="B24-vaccines-13-00175" ref-type="bibr">24</xref>], but this fact would affect both exposed and non-exposed infants. Fourthly, the possibility of parental laxity regarding basic hygiene measures for the prevention of respiratory infections, in the case of receiving nirsevimab. Fifthly, another possible explanation, in our opinion the most likely, is due to the existence of methodological biases. A selection bias due to the inclusion of hospitalised patients cannot be discarded. If nirsevimab reduces the severity of RSV infection, then the need for hospitalisation of an immunised infant is more likely to be due to the existence of other concomitant causes such as infections. It is also possible that infants selected to receive nirsevimab might have characteristics that predispose them to co-infections, including unmeasured confounders. Finally, there could exists a differential surveillance bias if microbiological tests are more frequently requested for immunised infants, possibly due to physicians&#x02019; misunderstanding of receiving RSV patients who had been administered with nirsevimab, in search of other pathogens that could explain the clinical presentation. We observed a slight tendency to perform more tests in this group, but not sufficient to completely explain the differences in co-infections. Of note, although infants administered with nirsevimab showed a higher frequency of co-infections, those infections were not associated with any adverse outcomes; instead, this subgroup showed less frequent PICU admission, mechanical ventilation, and a shorter total length of hospitalisation, which suggest that this finding might not be relevant for disease severity. In any case, future studies specifically designed to analyse this association are required.</p><p>We assumed that infants were not correctly immunised with nirsevimab unless they had received the passive immunisation at least 4 days before hospital admission. That decision was adopted considering the incubation period of the agent and the unknown time needed to reach adequate plasma levels after administration of nirsevimab. Some authors used 1 day to consider infants as protected [<xref rid="B18-vaccines-13-00175" ref-type="bibr">18</xref>] and others used up to 7 days [<xref rid="B25-vaccines-13-00175" ref-type="bibr">25</xref>]. At any rate, only one infant in our cohort was immunised during the 7 days before hospitalisation; thus, in our study the decision of choosing a cut-off point between 1 and 7 days (4 days in our case) would have not changed the results of the study.</p><p>We ascertained that none of the mothers of the infants included in the study had received RSV vaccination during pregnancy.</p><p>This study has certain limitations. We only included infants hospitalised due to RSV. As previously commented, non-population-based studies intrinsically have a certain degree of selection bias. In addition, the retrospective nature of data collection implies that we did not have information on potentially relevant variables (such us socioeconomic status, or other vaccines received during the campaign); therefore, residual confounding cannot be discarded. For feasibility reasons, we did not include all hospitals of Andalusia, but we selected those with higher number of admissions and PICU, including at least one hospital from each province. As a cohort study (not experimental design), data on the impact of the measure (passive immunisation with nirsevimab) should be considered cautiously. We showed impact measures such as the preventive fraction, but is should not be interpreted as completely causal due to the limitations exposed in this section. Finally, we did not have data on the length of certain outcomes, which prevented us from performing a survival analysis.</p><p>Future systematic reviews and meta-analyses are guaranteed to further understand the potential benefits of nirsevimab administration in infants, and specific studies should analyse data on co-infections. Besides. future long-term clinical trials are required to analyse the potential effects of this measure in future campaigns. We hope that the data presented from Andalusia in this study could help future public health decision making.</p></sec><sec sec-type="conclusions" id="sec5-vaccines-13-00175"><title>5. Conclusions</title><p>Passive immunisation with nirsevimab in infants &#x0003c; 6 months is associated with benefits in outcomes after hospitalisation due to RSV (respiratory support with a nasal cannula, mechanical ventilation, PICU admission, and the total length of hospitalisation), which suggest that this measure is effective beyond prevention of RSV infection or hospitalisation. Future specific studies should analyse the association of nirsevimab with co-infection and other in-hospital outcomes.</p></sec></body><back><ack><title>Acknowledgments</title><p>We thank the M&#x000e1;ster en Salud P&#x000fa;blica y Gesti&#x000f3;n Sanitaria (Escuela Andaluza de Salud P&#x000fa;blica) in its 2023&#x02013;2024 edition.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-vaccines-13-00175"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/vaccines13020175/s1">https://www.mdpi.com/article/10.3390/vaccines13020175/s1</uri>, Table S1: Characteristics of the hospitals and population reference included in the study; Table S2: Specific co-infections identified by exposure (nirsevimab, <italic toggle="yes">n</italic> = 127, no nirsevimab, <italic toggle="yes">n</italic> = 95).</p><supplementary-material id="vaccines-13-00175-s001" position="float" content-type="local-data"><media xlink:href="vaccines-13-00175-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, D.M.-P. and N.L.; methodology, D.M.-P., A.K., M.R.-I. and N.L.; formal analysis, A.K. and M.R.-I.; investigation, D.M.-P., A.K., F.d.B.C.-S., A.C.-M., O.D.-M., L.M.-C., E.P.-G., M.d.C.M.-P., J.L.S.-P., J.B.-G., M.I.S.-C., J.D.D.-S., M.R.-I. and N.L.; resources, D.M.-P.; data curation, A.K.; writing&#x02014;original draft preparation, D.M.-P., A.K. and M.R.-I.; writing&#x02014;review and editing, D.M.-P., A.K., F.d.B.C.-S., A.C.-M., O.D.-M., L.M.-C., E.P.-G., M.d.C.M.-P., J.L.S.-P., J.B.-G., M.I.S.-C., J.D.D.-S., M.R.-I. and N.L; project administration, D.M.-P., M.R.-I. and N.L. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The study was conducted in accordance with the Declaration of Helsinki and approved by the Biomedical Research Ethics Coordinating Committee of Andalusia (CCEIBA) on 28 June 2024, (registration code 202499907099520).</p></notes><notes><title>Informed Consent Statement</title><p>Patient consent was waived due to the retrospective nature of data collection, the anonymisation system for obtaining the database, the exclusion of potentially identifiable data, and the characteristics of the patients included in the study (vulnerable infants that required hospital admission during the last season).</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Data will be available upon reasonable request to the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><glossary><title>Abbreviations</title><p>The following abbreviations are used in this manuscript:
<array><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">aPF</td><td align="left" valign="middle" rowspan="1" colspan="1">Adjusted preventive fraction</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">aOR</td><td align="left" valign="middle" rowspan="1" colspan="1">Adjusted odds ratio</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">cRR</td><td align="left" valign="middle" rowspan="1" colspan="1">Crude risk ratio</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CI</td><td align="left" valign="middle" rowspan="1" colspan="1">Cumulative incidence</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">95%CI</td><td align="left" valign="middle" rowspan="1" colspan="1">95% confidence interval</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IR</td><td align="left" valign="middle" rowspan="1" colspan="1">Incidence rate</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IRR</td><td align="left" valign="middle" rowspan="1" colspan="1">Incidence rate ratio</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HR</td><td align="left" valign="middle" rowspan="1" colspan="1">Hazard ratio</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OR</td><td align="left" valign="middle" rowspan="1" colspan="1">Odds ratio</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PF</td><td align="left" valign="middle" rowspan="1" colspan="1">Preventive fraction</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PICU</td><td align="left" valign="middle" rowspan="1" colspan="1">Paediatric intensive care unit</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">RR</td><td align="left" valign="middle" rowspan="1" colspan="1">Risk ratio</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">RSV</td><td align="left" valign="middle" rowspan="1" colspan="1">Respiratory syncytial virus</td></tr></tbody></array></p></glossary><ref-list><title>References</title><ref id="B1-vaccines-13-00175"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Blau</surname><given-names>D.M.</given-names></name>
<name><surname>Caballero</surname><given-names>M.T.</given-names></name>
<name><surname>Feikin</surname><given-names>D.R.</given-names></name>
<name><surname>Gill</surname><given-names>C.J.</given-names></name>
<name><surname>Madhi</surname><given-names>S.A.</given-names></name>
<name><surname>Omer</surname><given-names>S.B.</given-names></name>
<name><surname>Sim&#x000f5;es</surname><given-names>E.A.F.</given-names></name>
<name><surname>Campbell</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: A systematic analysis</article-title><source>Lancet</source><year>2022</year><volume>399</volume><fpage>2047</fpage><lpage>2064</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(22)00478-0</pub-id><pub-id pub-id-type="pmid">35598608</pub-id>
</element-citation></ref><ref id="B2-vaccines-13-00175"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Weinberg</surname><given-names>G.A.</given-names></name>
</person-group><article-title>Respiratory syncytial virus mortality among young children</article-title><source>Lancet Glob. Health</source><year>2017</year><volume>5</volume><fpage>e951</fpage><lpage>e952</lpage><pub-id pub-id-type="doi">10.1016/S2214-109X(17)30348-0</pub-id><pub-id pub-id-type="pmid">28911753</pub-id>
</element-citation></ref><ref id="B3-vaccines-13-00175"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Treston</surname><given-names>B.</given-names></name>
<name><surname>Geoghegan</surname><given-names>S.</given-names></name>
</person-group><article-title>Exploring parental perspectives: Maternal RSV vaccination versus infant RSV monoclonal antibody</article-title><source>Hum. Vaccin. Immunother.</source><year>2024</year><volume>20</volume><fpage>2341505</fpage><pub-id pub-id-type="doi">10.1080/21645515.2024.2341505</pub-id><pub-id pub-id-type="pmid">38723786</pub-id>
</element-citation></ref><ref id="B4-vaccines-13-00175"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Britton</surname><given-names>A.</given-names></name>
<name><surname>Roper</surname><given-names>L.E.</given-names></name>
<name><surname>Kotton</surname><given-names>C.N.</given-names></name>
<name><surname>Hutton</surname><given-names>D.W.</given-names></name>
<name><surname>Fleming-Dutra</surname><given-names>K.E.</given-names></name>
<name><surname>Godfrey</surname><given-names>M.</given-names></name>
<name><surname>Ortega-Sanchez</surname><given-names>I.R.</given-names></name>
<name><surname>Broder</surname><given-names>K.R.</given-names></name>
<name><surname>Talbot</surname><given-names>H.K.</given-names></name>
<name><surname>Long</surname><given-names>S.S.</given-names></name>
<etal/>
</person-group><article-title>Use of Respiratory Syncytial Virus Vaccines in Adults Aged &#x02265;60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices&#x02014;United States, 2024</article-title><source>MMWR Morb. Mortal. Wkly. Rep.</source><year>2024</year><volume>73</volume><fpage>696</fpage><lpage>702</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm7332e1</pub-id><pub-id pub-id-type="pmid">39146277</pub-id>
</element-citation></ref><ref id="B5-vaccines-13-00175"><label>5.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>Agencia Espa&#x000f1;ola de Medicamentos y Productos Sanitarios</collab>
</person-group><article-title>Ficha T&#x000e9;cnica Beyfortus 100 mg Soluci&#x000f3;n Inyectable en Jeringa Precargada [Technical Datasheet Beyfortus 100 mg Solution for Injection in Prefilled Syringe]</article-title><comment>Available online: <ext-link xlink:href="https://cima.aemps.es/cima/dochtml/ft/1221689004/FT_1221689004.html" ext-link-type="uri">https://cima.aemps.es/cima/dochtml/ft/1221689004/FT_1221689004.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-01-03">(accessed on 3 January 2025)</date-in-citation></element-citation></ref><ref id="B6-vaccines-13-00175"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sim&#x000f5;es</surname><given-names>E.A.F.</given-names></name>
<name><surname>Madhi</surname><given-names>S.A.</given-names></name>
<name><surname>Muller</surname><given-names>W.J.</given-names></name>
<name><surname>Atanasova</surname><given-names>V.</given-names></name>
<name><surname>Bosheva</surname><given-names>M.</given-names></name>
<name><surname>Caba&#x000f1;as</surname><given-names>F.</given-names></name>
<name><surname>Baca Cots</surname><given-names>M.</given-names></name>
<name><surname>Domachowske</surname><given-names>J.B.</given-names></name>
<name><surname>Garcia-Garcia</surname><given-names>M.L.</given-names></name>
<name><surname>Grantina</surname><given-names>I.</given-names></name>
<etal/>
</person-group><article-title>Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: A pooled analysis of randomised controlled trials</article-title><source>Lancet Child. Adolesc. Health</source><year>2023</year><volume>7</volume><fpage>180</fpage><lpage>189</lpage><pub-id pub-id-type="pmid">36634694</pub-id>
</element-citation></ref><ref id="B7-vaccines-13-00175"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Griffin</surname><given-names>M.P.</given-names></name>
<name><surname>Yuan</surname><given-names>Y.</given-names></name>
<name><surname>Takas</surname><given-names>T.</given-names></name>
<name><surname>Domachowske</surname><given-names>J.B.</given-names></name>
<name><surname>Madhi</surname><given-names>S.A.</given-names></name>
<name><surname>Manzoni</surname><given-names>P.</given-names></name>
<name><surname>Sim&#x000f5;es</surname><given-names>E.A.F.</given-names></name>
<name><surname>Esser</surname><given-names>M.T.</given-names></name>
<name><surname>Khan</surname><given-names>A.A.</given-names></name>
<name><surname>Dubovsky</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants</article-title><source>N. Eng. J. Med.</source><year>2020</year><volume>383</volume><fpage>415</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1913556</pub-id><pub-id pub-id-type="pmid">32726528</pub-id>
</element-citation></ref><ref id="B8-vaccines-13-00175"><label>8.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>Ministerio de Sanidad, Gobierno de Espa&#x000f1;a</collab>
</person-group><article-title>Recomendaciones de Utilizaci&#x000f3;n de Nirsevimab Para la Prevenci&#x000f3;n del Virus Respiratorio Sincitial (VRS) Para la Temporada 2023&#x02013;2024 [Recommendations for the Use of Nirsevimab for the Prevention of respiratory Syncytial Virus (RSV) for the 2023&#x02013;2024 Season]</article-title><comment>Available online: <ext-link xlink:href="https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/comoTrabajamos/docs/Nirsevimab_2023.pdf" ext-link-type="uri">https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/comoTrabajamos/docs/Nirsevimab_2023.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-01-03">(accessed on 3 January 2025)</date-in-citation></element-citation></ref><ref id="B9-vaccines-13-00175"><label>9.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>Ministerio de Sanidad, Gobierno de Espa&#x000f1;a</collab>
</person-group><article-title>Actualizaci&#x000f3;n de Recomendaciones de Utilizaci&#x000f3;n de Nirsevimab [Update of Recommendations for the Use of Nirsevimab]</article-title><comment>Available online: <ext-link xlink:href="https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/comoTrabajamos/docs/NirsevimabActualizacion.pdf" ext-link-type="uri">https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/comoTrabajamos/docs/NirsevimabActualizacion.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-01-03">(accessed on 3 January 2025)</date-in-citation></element-citation></ref><ref id="B10-vaccines-13-00175"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Turalde-Mapili</surname><given-names>M.W.R.</given-names></name>
<name><surname>Mapili</surname><given-names>J.A.L.</given-names></name>
<name><surname>Turalde</surname><given-names>C.W.R.</given-names></name>
<name><surname>Pagcatipunan</surname><given-names>M.R.</given-names></name>
</person-group><article-title>The efficacy and safety of nirsevimab for the prevention of RSV infection among infants: A systematic review and meta-analysis</article-title><source>Front. Pediat.</source><year>2023</year><volume>11</volume><elocation-id>1132740</elocation-id><pub-id pub-id-type="doi">10.3389/fped.2023.1132740</pub-id></element-citation></ref><ref id="B11-vaccines-13-00175"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sun</surname><given-names>M.</given-names></name>
<name><surname>Lai</surname><given-names>H.</given-names></name>
<name><surname>Na</surname><given-names>F.</given-names></name>
<name><surname>Li</surname><given-names>S.</given-names></name>
<name><surname>Qiu</surname><given-names>X.</given-names></name>
<name><surname>Tian</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>Z.</given-names></name>
<name><surname>Ge</surname><given-names>L.</given-names></name>
</person-group><article-title>Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children: A Systematic Review and Network Meta-analysis</article-title><source>JAMA Netw. Open</source><year>2023</year><volume>6</volume><fpage>e230023</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2023.0023</pub-id><pub-id pub-id-type="pmid">36800182</pub-id>
</element-citation></ref><ref id="B12-vaccines-13-00175"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ricc&#x000f2;</surname><given-names>M.</given-names></name>
<name><surname>Cascio</surname><given-names>A.</given-names></name>
<name><surname>Corrado</surname><given-names>S.</given-names></name>
<name><surname>Bottazzoli</surname><given-names>M.</given-names></name>
<name><surname>Marchesi</surname><given-names>F.</given-names></name>
<name><surname>Gili</surname><given-names>R.</given-names></name>
<name><surname>Giuri</surname><given-names>P.G.</given-names></name>
<name><surname>Gori</surname><given-names>D.</given-names></name>
<name><surname>Manzoni</surname><given-names>P.</given-names></name>
</person-group><article-title>Impact of Nirsevimab Immunization on Pediatric Hospitalization Rates: A Systematic Review and Meta-Analysis (2024)</article-title><source>Vaccines</source><year>2024</year><volume>12</volume><elocation-id>640</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines12060640</pub-id><pub-id pub-id-type="pmid">38932369</pub-id>
</element-citation></ref><ref id="B13-vaccines-13-00175"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Drysdale</surname><given-names>S.B.</given-names></name>
<name><surname>Cathie</surname><given-names>K.</given-names></name>
<name><surname>Flamein</surname><given-names>F.</given-names></name>
<name><surname>Knuf</surname><given-names>M.</given-names></name>
<name><surname>Collins</surname><given-names>A.M.</given-names></name>
<name><surname>Hill</surname><given-names>H.C.</given-names></name>
<name><surname>Kaiser</surname><given-names>F.</given-names></name>
<name><surname>Cohen</surname><given-names>R.</given-names></name>
<name><surname>Pinquier</surname><given-names>D.</given-names></name>
<name><surname>Felter</surname><given-names>C.T.</given-names></name>
<etal/>
</person-group><article-title>Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants</article-title><source>N. Eng. J. Med.</source><year>2023</year><volume>389</volume><fpage>2425</fpage><lpage>2435</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2309189</pub-id><pub-id pub-id-type="pmid">38157500</pub-id>
</element-citation></ref><ref id="B14-vaccines-13-00175"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kuitunen</surname><given-names>I.</given-names></name>
<name><surname>Backman</surname><given-names>K.</given-names></name>
<name><surname>G&#x000e4;rdstr&#x000f6;m</surname><given-names>E.</given-names></name>
<name><surname>Renko</surname><given-names>M.</given-names></name>
</person-group><article-title>Monoclonal antibody therapies in respiratory syncytial virus prophylaxis-An umbrella review</article-title><source>Pediat. Pulmonol.</source><year>2024</year><volume>59</volume><fpage>2374</fpage><lpage>2380</lpage><pub-id pub-id-type="doi">10.1002/ppul.27041</pub-id><pub-id pub-id-type="pmid">38751021</pub-id>
</element-citation></ref><ref id="B15-vaccines-13-00175"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>von Elm</surname><given-names>E.</given-names></name>
<name><surname>Altman</surname><given-names>D.G.</given-names></name>
<name><surname>Egger</surname><given-names>M.</given-names></name>
<name><surname>Pocock</surname><given-names>S.J.</given-names></name>
<name><surname>G&#x000f8;tzsche</surname><given-names>P.C.</given-names></name>
<name><surname>Vandenbroucke</surname><given-names>J.P.</given-names></name>
<collab>STROBE Initiative</collab>
</person-group><article-title>The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies</article-title><source>Lancet</source><year>2007</year><volume>370</volume><fpage>1453</fpage><lpage>1457</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(07)61602-X</pub-id><pub-id pub-id-type="pmid">18064739</pub-id>
</element-citation></ref><ref id="B16-vaccines-13-00175"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ares-G&#x000f3;mez</surname><given-names>S.</given-names></name>
<name><surname>Mallah</surname><given-names>N.</given-names></name>
<name><surname>Santiago-P&#x000e9;rez</surname><given-names>M.I.</given-names></name>
<name><surname>Pardo-Seco</surname><given-names>J.</given-names></name>
<name><surname>P&#x000e9;rez-Mart&#x000ed;nez</surname><given-names>O.</given-names></name>
<name><surname>Otero-Barr&#x000f3;s</surname><given-names>M.T.</given-names></name>
<name><surname>Su&#x000e1;rez-Gaiche</surname><given-names>N.</given-names></name>
<name><surname>Kramer</surname><given-names>R.</given-names></name>
<name><surname>Jin</surname><given-names>J.</given-names></name>
<name><surname>Platero-Alonso</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: Initial results of a population-based longitudinal study</article-title><source>Lancet Infect. Dis.</source><year>2024</year><volume>24</volume><fpage>817</fpage><lpage>828</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(24)00215-9</pub-id><pub-id pub-id-type="pmid">38701823</pub-id>
</element-citation></ref><ref id="B17-vaccines-13-00175"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>L&#x000f3;pez-Lacort</surname><given-names>M.</given-names></name>
<name><surname>Mu&#x000f1;oz-Quiles</surname><given-names>C.</given-names></name>
<name><surname>Mira-Iglesias</surname><given-names>A.</given-names></name>
<name><surname>L&#x000f3;pez-Labrador</surname><given-names>F.X.</given-names></name>
<name><surname>Mengual-Chuli&#x000e1;</surname><given-names>B.</given-names></name>
<name><surname>Fern&#x000e1;ndez-Garc&#x000ed;a</surname><given-names>C.</given-names></name>
<name><surname>Carballido-Fern&#x000e1;ndez</surname><given-names>M.</given-names></name>
<name><surname>Pineda-Caplliure</surname><given-names>A.</given-names></name>
<name><surname>Mollar-Maseres</surname><given-names>J.</given-names></name>
<name><surname>Shalabi Benavent</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024</article-title><source>Euro Surveill.</source><year>2024</year><volume>29</volume><fpage>2400046</fpage><pub-id pub-id-type="doi">10.2807/1560-7917.ES.2024.29.6.2400046</pub-id><pub-id pub-id-type="pmid">38333937</pub-id>
</element-citation></ref><ref id="B18-vaccines-13-00175"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barbas Del Buey</surname><given-names>J.F.</given-names></name>
<name><surname>&#x000cd;&#x000f1;igo Mart&#x000ed;nez</surname><given-names>J.</given-names></name>
<name><surname>Guti&#x000e9;rrez Rodr&#x000ed;guez</surname><given-names>M.&#x000c1;.</given-names></name>
<name><surname>Alonso Garc&#x000ed;a</surname><given-names>M.</given-names></name>
<name><surname>S&#x000e1;nchez-G&#x000f3;mez</surname><given-names>A.</given-names></name>
<name><surname>Lasheras Carbajo</surname><given-names>M.D.</given-names></name>
<name><surname>Jim&#x000e9;nez Bueno</surname><given-names>S.</given-names></name>
<name><surname>Esteban Vasallo</surname><given-names>M.D.</given-names></name>
<name><surname>L&#x000f3;pez Zambrano</surname><given-names>M.A.</given-names></name>
<name><surname>Calvo Rey</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>The effectiveness of nirsevimab in reducing the burden of disease due to respiratory syncytial virus (RSV) infection over time in the Madrid region (Spain): A prospective population-based cohort study</article-title><source>Front. Public Health</source><year>2024</year><volume>12</volume><elocation-id>1441786</elocation-id><pub-id pub-id-type="doi">10.3389/fpubh.2024.1441786</pub-id><pub-id pub-id-type="pmid">39220460</pub-id>
</element-citation></ref><ref id="B19-vaccines-13-00175"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Coma</surname><given-names>E.</given-names></name>
<name><surname>Martinez-Marcos</surname><given-names>M.</given-names></name>
<name><surname>Hermosilla</surname><given-names>E.</given-names></name>
<name><surname>Mendioroz</surname><given-names>J.</given-names></name>
<name><surname>Re&#x000f1;&#x000e9;</surname><given-names>A.</given-names></name>
<name><surname>Fina</surname><given-names>F.</given-names></name>
<name><surname>Perramon-Malavez</surname><given-names>A.</given-names></name>
<name><surname>Prats</surname><given-names>C.</given-names></name>
<name><surname>Cereza</surname><given-names>G.</given-names></name>
<name><surname>Ciruela</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital and primary care settings: A retrospective cohort study in infants in Catalonia (Spain)</article-title><source>Arch. Dis. Child.</source><year>2024</year><volume>109</volume><fpage>736</fpage><lpage>741</lpage><pub-id pub-id-type="doi">10.1136/archdischild-2024-327153</pub-id><pub-id pub-id-type="pmid">38857952</pub-id>
</element-citation></ref><ref id="B20-vaccines-13-00175"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mazagatos</surname><given-names>C.</given-names></name>
<name><surname>Mendioroz</surname><given-names>J.</given-names></name>
<name><surname>Rumayor</surname><given-names>M.B.</given-names></name>
<name><surname>Gallardo Garc&#x000ed;a</surname><given-names>V.</given-names></name>
<name><surname>&#x000c1;lvarez R&#x000ed;o</surname><given-names>V.</given-names></name>
<name><surname>Cebollada Gracia</surname><given-names>A.D.</given-names></name>
<name><surname>Batalla Rebollo</surname><given-names>N.</given-names></name>
<name><surname>Barranco Boada</surname><given-names>M.I.</given-names></name>
<name><surname>P&#x000e9;rez-Mart&#x000ed;nez</surname><given-names>O.</given-names></name>
<name><surname>Lameiras Azevedo</surname><given-names>A.S.</given-names></name>
<etal/>
</person-group><article-title>Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children &#x0003c; 1&#x02009;Year, Weeks 40, 2023, to 8, 2024, Spain</article-title><source>Influenza Other Respir. Viruses</source><year>2024</year><volume>18</volume><fpage>e13294</fpage><pub-id pub-id-type="pmid">38716791</pub-id>
</element-citation></ref><ref id="B21-vaccines-13-00175"><label>21.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>Spanish Ministry of Health</collab>
</person-group><article-title>Evaluaci&#x000f3;n de la Vacunaci&#x000f3;n Frente a VRS en la Poblaci&#x000f3;n Adulta [Evaluation of RSV Vaccination in Adult Population]</article-title><comment>Available online: <ext-link xlink:href="https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/comoTrabajamos/docs/VRS_adultos.pdf" ext-link-type="uri">https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/comoTrabajamos/docs/VRS_adultos.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-01-26">(accessed on 26 January 2025)</date-in-citation></element-citation></ref><ref id="B22-vaccines-13-00175"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jeziorski</surname><given-names>E.</given-names></name>
<name><surname>Ouziel</surname><given-names>A.</given-names></name>
<name><surname>Cotillon</surname><given-names>M.</given-names></name>
<name><surname>Bridonneau</surname><given-names>C.</given-names></name>
<name><surname>Bizot</surname><given-names>E.</given-names></name>
<name><surname>Basse</surname><given-names>C.</given-names></name>
<name><surname>Portefaix</surname><given-names>A.</given-names></name>
<name><surname>Dubos</surname><given-names>F.</given-names></name>
<name><surname>B&#x000e9;chet</surname><given-names>S.M.</given-names></name>
<name><surname>Domitien</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Impact of nirsevimab on respiratory syncytial virus bronchiolitis in hospitalized infants: A real-world study</article-title><source>Pediatr. Infect. Dis. J.</source><year>2024</year><volume>10</volume><fpage>1097</fpage><pub-id pub-id-type="doi">10.1097/INF.0000000000004630</pub-id></element-citation></ref><ref id="B23-vaccines-13-00175"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sender</surname><given-names>V.</given-names></name>
<name><surname>Hentrich</surname><given-names>K.</given-names></name>
<name><surname>Henriques-Normark</surname><given-names>B.</given-names></name>
</person-group><article-title>Virus-induced changes of the respiratory tract environment promote secondary infections with <italic toggle="yes">Streptococcus pneumoniae</italic></article-title><source>Front. Cell Infect. Microbiol.</source><year>2021</year><volume>11</volume><elocation-id>643326</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2021.643326</pub-id><pub-id pub-id-type="pmid">33828999</pub-id>
</element-citation></ref><ref id="B24-vaccines-13-00175"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chatzopoulou</surname><given-names>F.</given-names></name>
<name><surname>Gioula</surname><given-names>G.</given-names></name>
<name><surname>Kioumis</surname><given-names>I.</given-names></name>
<name><surname>Chatzidimitriou</surname><given-names>D.</given-names></name>
<name><surname>Exindari</surname><given-names>M.</given-names></name>
</person-group><article-title>Identification of complement-related host genetic risk factors associated with influenza A(H1N1)pdm09 outcome: Challenges ahead</article-title><source>Med. Microbiol. Immunol.</source><year>2019</year><volume>208</volume><fpage>631</fpage><lpage>640</lpage><pub-id pub-id-type="doi">10.1007/s00430-018-0567-9</pub-id><pub-id pub-id-type="pmid">30306260</pub-id>
</element-citation></ref><ref id="B25-vaccines-13-00175"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moline</surname><given-names>H.L.</given-names></name>
<name><surname>Tannis</surname><given-names>A.</given-names></name>
<name><surname>Toepfer</surname><given-names>A.P.</given-names></name>
<name><surname>Williams</surname><given-names>J.V.</given-names></name>
<name><surname>Boom</surname><given-names>J.A.</given-names></name>
<name><surname>Englund</surname><given-names>J.A.</given-names></name>
<name><surname>Halasa</surname><given-names>N.B.</given-names></name>
<name><surname>Staat</surname><given-names>M.A.</given-names></name>
<name><surname>Weinberg</surname><given-names>G.A.</given-names></name>
<name><surname>Selvarangan</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus&#x02013;Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season&#x02014;New Vaccine Surveillance Network, October 2023&#x02013;February 2024</article-title><source>MMWR Morb. Mortal. Wkly. Rep.</source><year>2024</year><volume>73</volume><fpage>209</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm7309a4</pub-id><pub-id pub-id-type="pmid">38457312</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="vaccines-13-00175-f001"><label>Figure 1</label><caption><p>Flow chart of the study sample selection.</p></caption><graphic xlink:href="vaccines-13-00175-g001" position="float"/></fig><fig position="float" id="vaccines-13-00175-f002"><label>Figure 2</label><caption><p>Kaplan&#x02013;Meier curves for temporal outcomes stratified by exposure to nirsevimab (X axis: number of days; Y axis: probability).</p></caption><graphic xlink:href="vaccines-13-00175-g002" position="float"/></fig><table-wrap position="float" id="vaccines-13-00175-t001"><object-id pub-id-type="pii">vaccines-13-00175-t001_Table 1</object-id><label>Table 1</label><caption><p>Baseline characteristics of the sample of infants hospitalised due to RSV during the 2023&#x02013;2024 campaign in Andalusia, Spain.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Characteristics at Admission</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Total</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Passive Immunisation with Nirsevimab</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes (<italic toggle="yes">n</italic> = 127)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No (<italic toggle="yes">n</italic> = 95)</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Sex, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;Men</td><td align="center" valign="middle" rowspan="1" colspan="1">133 (59.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">82 (64.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">51 (53.7)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;Women</td><td align="center" valign="middle" rowspan="1" colspan="1">89 (40.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">45 (35.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">44 (46.3)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">University Hospital (UH), <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;UH Virgen del Roc&#x000ed;o, Sevilla</td><td align="center" valign="middle" rowspan="1" colspan="1">50 (22.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">22 (17.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">28 (29.5)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;Regional UH Malaga</td><td align="center" valign="middle" rowspan="1" colspan="1">39 (17.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">21 (16.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">18 (19)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;UH Reina Sof&#x000ed;a, Cordoba</td><td align="center" valign="middle" rowspan="1" colspan="1">28 (12.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">19 (15.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (9.5)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;UH Torrec&#x000e1;rdenas Almer&#x000ed;a</td><td align="center" valign="middle" rowspan="1" colspan="1">23 (10.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">10 (7.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">13 (13.7)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;UH Virgen Macarena, Sevilla</td><td align="center" valign="middle" rowspan="1" colspan="1">23 (10.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">14 (11.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (9.5)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;UH Ja&#x000e9;n</td><td align="center" valign="middle" rowspan="1" colspan="1">21 (9.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">16 (12.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (5.3)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;UH Virgen de las Nieves, Granada</td><td align="center" valign="middle" rowspan="1" colspan="1">14 (6.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (6.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (6.3)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;UH Juan Ram&#x000f3;n Jim&#x000e9;nez, Huelva</td><td align="center" valign="middle" rowspan="1" colspan="1">13 (5.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (6.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (5.3)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;&#x000a0;UH Puerta del Mar, C&#x000e1;diz</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (5.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (7.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (2.1)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Age at admission in days, median (IQR)</td><td align="center" valign="middle" rowspan="1" colspan="1">59 (71)</td><td align="center" valign="middle" rowspan="1" colspan="1">66 (55.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">45 (99.5)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Use of FilmArray, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">44 (19.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">28 (22.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">16 (16.8)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Any baseline disease, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">13 (5.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">10 (7.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (3.2)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Congenital heart disease, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7 (3.2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 (4.7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (1.1)</td></tr></tbody></table><table-wrap-foot><fn><p>IQR, interquartile range; <italic toggle="yes">n</italic> (%), absolute frequency (relative frequency); UH, university hospital.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-13-00175-t002"><object-id pub-id-type="pii">vaccines-13-00175-t002_Table 2</object-id><label>Table 2</label><caption><p>Bivariate associations between exposure (passive immunisation with nirsevimab) and the outcomes analysed during hospitalisation.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Outcomes During Hospitalisation (Follow-Up)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Total</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Passive Immunisation with Nirsevimab</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes (<italic toggle="yes">n</italic> = 127)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No (<italic toggle="yes">n</italic> = 95)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Respiratory support, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">198 (89.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">109 (85.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">89 (93.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.062 <sup>1</sup></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Conventional nasal cannula, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">187 (84.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">101 (79.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">86 (90.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.026 <sup>1</sup></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">High-flow oxygen therapy, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">43 (19.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">28 (22.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">15 (15.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.245 <sup>1</sup></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Mechanical ventilation (invasive o non-invasive), <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">89 (40.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">41 (32.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">48 (50.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.006 <sup>1</sup></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Invasive mechanical ventilation, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (3.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (3.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (2.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.701 <sup>3</sup></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Nasogastric tube, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">102 (46.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">51 (40.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">51 (53.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.045 <sup>1</sup></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Intravenous access, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">121 (54.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">67 (52.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">54 (56.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.545 <sup>1</sup></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Antibiotic use, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">40 (18.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">24 (18.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">16 (16.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.693 <sup>1</sup></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Chest imaging diagnostics, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">97 (43.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">49 (38.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">48 (50.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.076 <sup>1</sup></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Co-infection, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">46 (20.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">35 (27.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (11.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.004 <sup>1</sup></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PICU admission, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">99 (44.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">46 (36.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">53 (55.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.004 <sup>1</sup></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Mechanical ventilation in PICU, <italic toggle="yes">n</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">38 (17.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">17 (13.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">21 (22.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.088 <sup>1</sup></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Length of PICU hospitalisation, median (IQR)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (5)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (4)</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (4)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.167 <sup>2</sup></td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total length of hospitalisation, median (IQR)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 (5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 (3.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7 (5.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.003 <sup>2</sup></td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup> Chi-square test, <sup>2</sup> Mann&#x02013;Whitney test, <sup>3</sup> Fisher&#x02019;s exact test. <italic toggle="yes">n</italic> (%), Absolute frequency (relative frequency); IQR, interquartile range.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-13-00175-t003"><object-id pub-id-type="pii">vaccines-13-00175-t003_Table 3</object-id><label>Table 3</label><caption><p>Cumulative incidence, crude relative risks, and nirsevimab effectiveness (preventive fraction) for dichotomous outcomes analysed during hospitalisation due to RSV in infants aged &#x0003c; 6 months.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Outcomes During Follow-Up (Hospitalisation)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CIe<break/>(Nirsevimab)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CIo<break/>(no Nirsevimab)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">RR (IC95%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Effectiveness, PF (IC95%)</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Respiratory support</td><td align="center" valign="middle" rowspan="1" colspan="1">85.8%</td><td align="center" valign="middle" rowspan="1" colspan="1">93.7%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.92 (0.84&#x02013;1.00)</td><td align="center" valign="middle" rowspan="1" colspan="1">8.4% (0.0&#x02013;16.1)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Conventional nasal cannula</td><td align="center" valign="middle" rowspan="1" colspan="1">79.5%</td><td align="center" valign="middle" rowspan="1" colspan="1">90.5%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.88 (0.79&#x02013;0.98)</td><td align="center" valign="middle" rowspan="1" colspan="1">12.1% (2.0&#x02013;21.3)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">High-flow oxygen therapy</td><td align="center" valign="middle" rowspan="1" colspan="1">22.0%</td><td align="center" valign="middle" rowspan="1" colspan="1">15.8%</td><td align="center" valign="middle" rowspan="1" colspan="1">1.40 (0.79&#x02013;2.46)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Mechanical ventilation (invasive or non-invasive)</td><td align="center" valign="middle" rowspan="1" colspan="1">32.3%</td><td align="center" valign="middle" rowspan="1" colspan="1">50.5%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.63 (0.37&#x02013;1.10)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Invasive mechanical ventilation</td><td align="center" valign="middle" rowspan="1" colspan="1">3.9%</td><td align="center" valign="middle" rowspan="1" colspan="1">2.1%</td><td align="center" valign="middle" rowspan="1" colspan="1">1.87 (0.35&#x02013;9.85)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Nasogastric tube</td><td align="center" valign="middle" rowspan="1" colspan="1">40.2%</td><td align="center" valign="middle" rowspan="1" colspan="1">53.7%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.75 (0.56&#x02013;0.99)</td><td align="center" valign="middle" rowspan="1" colspan="1">25.2% (0.0&#x02013;43.6)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Intravenous access</td><td align="center" valign="middle" rowspan="1" colspan="1">52.8%</td><td align="center" valign="middle" rowspan="1" colspan="1">56.8%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.93 (0.73&#x02013;1.18)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Antibiotic use</td><td align="center" valign="middle" rowspan="1" colspan="1">18.9%</td><td align="center" valign="middle" rowspan="1" colspan="1">16.8%</td><td align="center" valign="middle" rowspan="1" colspan="1">1.12 (0.63&#x02013;1.99)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Chest imaging tests</td><td align="center" valign="middle" rowspan="1" colspan="1">38.6%</td><td align="center" valign="middle" rowspan="1" colspan="1">50.5%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.76 (0.57&#x02013;1.03)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Co-infection</td><td align="center" valign="middle" rowspan="1" colspan="1">27.6%</td><td align="center" valign="middle" rowspan="1" colspan="1">11.6%</td><td align="center" valign="middle" rowspan="1" colspan="1">2.38 (1.28&#x02013;4.44)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PICU admission</td><td align="center" valign="middle" rowspan="1" colspan="1">36.2%</td><td align="center" valign="middle" rowspan="1" colspan="1">55.8%</td><td align="center" valign="middle" rowspan="1" colspan="1">0.65 (0.48&#x02013;0.87)</td><td align="center" valign="middle" rowspan="1" colspan="1">35.1% (13.1&#x02013;51.5)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Invasive o non-invasive mechanical ventilation in PICU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13.4%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22.1%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.61 (0.34&#x02013;1.08)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr></tbody></table><table-wrap-foot><fn><p>CIe, cumulative incidence in the exposed group (passive immunisation with nirsevimab); CIo, cumulative incidence in the non-exposed group (no passive immunisation with nirsevimab); RR, risk ratio (unadjusted); PF, preventive fraction (as a measure of impact of nirsevimab effectiveness).</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-13-00175-t004"><object-id pub-id-type="pii">vaccines-13-00175-t004_Table 4</object-id><label>Table 4</label><caption><p>Incidence rate, crude incidence rate ratios, and effectiveness for the dichotomous outcomes analysed during hospitalisation due to RSV in infants aged &#x0003c; 6 months.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Outcomes</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">IR (Total Sample)</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">IRe (Nirsevimab<break/>Administration)</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">IRo (no Nirsevimab<break/>Administration)</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">IRR (IC95%)</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">PF (IC95%)</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cases/<break/>Patients-Day</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IR per 100 Patients-Day</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cases/<break/>Patients-Day</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IR per 100<break/>Patients-Day</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cases/<break/>Patients-Day</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IR per 100<break/>Patients-Day</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Respiratory support</td><td align="center" valign="middle" rowspan="1" colspan="1">198/347</td><td align="center" valign="middle" rowspan="1" colspan="1">57.06</td><td align="center" valign="middle" rowspan="1" colspan="1">109/209</td><td align="center" valign="middle" rowspan="1" colspan="1">52.15</td><td align="center" valign="middle" rowspan="1" colspan="1">89/138</td><td align="center" valign="middle" rowspan="1" colspan="1">64.49</td><td align="center" valign="middle" rowspan="1" colspan="1">0.81 (0.61&#x02013;1.07)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Conventional nasal cannula</td><td align="center" valign="middle" rowspan="1" colspan="1">187/826</td><td align="center" valign="middle" rowspan="1" colspan="1">22.64</td><td align="center" valign="middle" rowspan="1" colspan="1">101/478</td><td align="center" valign="middle" rowspan="1" colspan="1">21.13</td><td align="center" valign="middle" rowspan="1" colspan="1">86/348</td><td align="center" valign="middle" rowspan="1" colspan="1">24.71</td><td align="center" valign="middle" rowspan="1" colspan="1">0.86 (0.64&#x02013;1.14)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">High-flow oxygen therapy</td><td align="center" valign="middle" rowspan="1" colspan="1">43/1563</td><td align="center" valign="middle" rowspan="1" colspan="1">2.75</td><td align="center" valign="middle" rowspan="1" colspan="1">28/780</td><td align="center" valign="middle" rowspan="1" colspan="1">3.59</td><td align="center" valign="middle" rowspan="1" colspan="1">15/783</td><td align="center" valign="middle" rowspan="1" colspan="1">1.92</td><td align="center" valign="middle" rowspan="1" colspan="1">1.87 (1.00&#x02013;3.51)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Mechanical ventilation (invasive or non-invasive)</td><td align="center" valign="middle" rowspan="1" colspan="1">88/1386</td><td align="center" valign="middle" rowspan="1" colspan="1">6.35</td><td align="center" valign="middle" rowspan="1" colspan="1">41/926</td><td align="center" valign="middle" rowspan="1" colspan="1">4.43</td><td align="center" valign="middle" rowspan="1" colspan="1">47/460</td><td align="center" valign="middle" rowspan="1" colspan="1">10.22</td><td align="center" valign="middle" rowspan="1" colspan="1">0.43 (0.29&#x02013;0.66)</td><td align="center" valign="middle" rowspan="1" colspan="1">56.7% (34.1&#x02013;71.5%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Invasive mechanical ventilation</td><td align="center" valign="middle" rowspan="1" colspan="1">7/1731</td><td align="center" valign="middle" rowspan="1" colspan="1">0.40</td><td align="center" valign="middle" rowspan="1" colspan="1">5/882</td><td align="center" valign="middle" rowspan="1" colspan="1">0.57</td><td align="center" valign="middle" rowspan="1" colspan="1">2/849</td><td align="center" valign="middle" rowspan="1" colspan="1">0.24</td><td align="center" valign="middle" rowspan="1" colspan="1">2.41 (0.39&#x02013;25.27)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Nasogastric tube</td><td align="center" valign="middle" rowspan="1" colspan="1">102/948</td><td align="center" valign="middle" rowspan="1" colspan="1">10.76</td><td align="center" valign="middle" rowspan="1" colspan="1">51/521</td><td align="center" valign="middle" rowspan="1" colspan="1">9.79</td><td align="center" valign="middle" rowspan="1" colspan="1">51/427</td><td align="center" valign="middle" rowspan="1" colspan="1">11.94</td><td align="center" valign="middle" rowspan="1" colspan="1">0.82 (0.56&#x02013;1.21)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Antibiotic use</td><td align="center" valign="middle" rowspan="1" colspan="1">40/1552</td><td align="center" valign="middle" rowspan="1" colspan="1">2.58</td><td align="center" valign="middle" rowspan="1" colspan="1">24/765</td><td align="center" valign="middle" rowspan="1" colspan="1">3.14</td><td align="center" valign="middle" rowspan="1" colspan="1">16/787</td><td align="center" valign="middle" rowspan="1" colspan="1">2.03</td><td align="center" valign="middle" rowspan="1" colspan="1">1.54 (0.82&#x02013;2.90)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PICU admission</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99/857</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11.55</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">46/547</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.41</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">53/310</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.49 (0.33&#x02013;0.73)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50.8% (27.0&#x02013;66.9%)</td></tr></tbody></table><table-wrap-foot><fn><p>IRe, incidence rate in the exposed group (nirsevimab administration); IRo, incidence rate in the non-exposed group (no nirsevimab administration); IRR, incidence rate ratio (unadjusted); PF, preventive fraction. Incidence rates were calculated as number of new cases of each outcome during hospitalisation/total time the population was at risk for this outcome during hospitalisation (sum of total length of hospitalisation for patients that did not develop the outcome plus time from admission to outcome development for patients that developed each outcome). No data on dates were available for intravenous access, co-infection, chest imaging tests, and mechanical ventilation in PICU in our database; therefore, incidence rates could not be calculated for these outcomes.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-13-00175-t005"><object-id pub-id-type="pii">vaccines-13-00175-t005_Table 5</object-id><label>Table 5</label><caption><p>Multivariable analysis of the adjusted association between nirsevimab and the dichotomous outcomes analysed during hospitalisation due to RSV in infants aged &#x0003c; 6 months.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Outcome</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">cOR (IC95%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">aOR (IC95%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Effectiveness. aPF</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Respiratory support</td><td align="center" valign="middle" rowspan="1" colspan="1">0.41 (0.16&#x02013;1.07)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.38 (0.14&#x02013;1.03)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Conventional nasal cannula</td><td align="center" valign="middle" rowspan="1" colspan="1">0.41 (0.18&#x02013;0.91)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.36 (0.15&#x02013;0.87)</td><td align="center" valign="middle" rowspan="1" colspan="1">64% (13&#x02013;85%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">High-flow oxygen therapy</td><td align="center" valign="middle" rowspan="1" colspan="1">1.51 (0.75&#x02013;3.02)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.32 (0.58&#x02013;3.00)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Mechanical ventilation (invasive or non-invasive)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.47 (0.27&#x02013;0.81)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.52 (0.27&#x02013;0.99)</td><td align="center" valign="middle" rowspan="1" colspan="1">48% (1&#x02013;73%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Invasive mechanical ventilation</td><td align="center" valign="middle" rowspan="1" colspan="1">1.91 (0.36&#x02013;10.04)</td><td align="center" valign="middle" rowspan="1" colspan="1">3.52 (0.55&#x02013;22.56)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Nasogastric tube</td><td align="center" valign="middle" rowspan="1" colspan="1">0.58 (0.34&#x02013;0.99)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.62 (0.34&#x02013;1.13)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Intravenous access</td><td align="center" valign="middle" rowspan="1" colspan="1">0.85 (0.88&#x02013;1.98)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.07 (0.57&#x02013;2.00)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Antibiotic use</td><td align="center" valign="middle" rowspan="1" colspan="1">1.15 (0.57&#x02013;2.31)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.26 (0.60&#x02013;2.66)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Chest imaging tests</td><td align="center" valign="middle" rowspan="1" colspan="1">0.62 (0.36&#x02013;1.05)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.73 (0.39&#x02013;1.35)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Co-infection</td><td align="center" valign="middle" rowspan="1" colspan="1">2.91 (1.39&#x02013;6.08)</td><td align="center" valign="middle" rowspan="1" colspan="1">3.42 (1.52&#x02013;7.68)</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PICU admission</td><td align="center" valign="middle" rowspan="1" colspan="1">0.45 (0.26&#x02013;0.77)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.46 (0.25&#x02013;0.86)</td><td align="center" valign="middle" rowspan="1" colspan="1">54% (14&#x02013;75%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mechanical ventilation in PICU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.54 (0.27&#x02013;1.10)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.74 (0.27&#x02013;2.05)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr></tbody></table><table-wrap-foot><fn><p>cOR, crude odds ratio; aOR, adjusted odds ratio; aPF, adjusted prevention fraction.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-13-00175-t006"><object-id pub-id-type="pii">vaccines-13-00175-t006_Table 6</object-id><label>Table 6</label><caption><p>Adjusted associations between nirsevimab passive immunisation and temporal outcomes during hospitalisation due to RSV in infants aged &#x0003c; 6 months.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Outcome</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Patients</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Exposed<break/>(Nirsevimab), Days</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Not Exposed (No<break/>Nirsevimab), Days</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Log-Rank Test<break/><italic toggle="yes">p</italic>-Value</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">cHR (IC95%) for Being Administered with Nirsevimab</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">aHR (IC95%) for<break/>Being Administered<break/>with Nirsevimab</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Median (IQR)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mean (sd)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Median (IQR)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mean (sd)</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Total length of hospitalisation </td><td align="center" valign="middle" rowspan="1" colspan="1">222</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (4&#x02013;8)</td><td align="center" valign="middle" rowspan="1" colspan="1">6.62 (4.58)</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (5&#x02013;11)</td><td align="center" valign="middle" rowspan="1" colspan="1">8.47 (5.79)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.005</td><td align="center" valign="middle" rowspan="1" colspan="1">0.68 (0.52&#x02013;0.89)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.70 (0.53&#x02013;0.92)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Length of respiratory support </td><td align="center" valign="middle" rowspan="1" colspan="1">198</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (3&#x02013;6)</td><td align="center" valign="middle" rowspan="1" colspan="1">5.56 (4.26)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (4&#x02013;9)</td><td align="center" valign="middle" rowspan="1" colspan="1">6.81 (4.87)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.048</td><td align="center" valign="middle" rowspan="1" colspan="1">0.76 (0.57&#x02013;1.01)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.75 (0.56&#x02013;1.01)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Length of nasal cannula usage </td><td align="center" valign="middle" rowspan="1" colspan="1">187</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (2&#x02013;4)</td><td align="center" valign="middle" rowspan="1" colspan="1">3.24 (1.68)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (2&#x02013;5)</td><td align="center" valign="middle" rowspan="1" colspan="1">4.12 (3.19)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.020</td><td align="center" valign="middle" rowspan="1" colspan="1">0.71 (0.53&#x02013;0.95)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.69 (0.51&#x02013;0.93)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Length of high-flow oxygen therapy </td><td align="center" valign="middle" rowspan="1" colspan="1">43</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (1&#x02013;4)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.75 (1.86)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (1&#x02013;4)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.87 (1.64)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.958</td><td align="center" valign="middle" rowspan="1" colspan="1">1.04 (0.55&#x02013;1.97)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.07 (0.51&#x02013;2.28)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Length of mechanical ventilation <sup>1</sup>
</td><td align="center" valign="middle" rowspan="1" colspan="1">89</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (2&#x02013;7)</td><td align="center" valign="middle" rowspan="1" colspan="1">5.03 (4.72)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (2&#x02013;6)</td><td align="center" valign="middle" rowspan="1" colspan="1">4.35 (3.17)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.471</td><td align="center" valign="middle" rowspan="1" colspan="1">1.14 (0.75&#x02013;1.73)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.12 (0.71&#x02013;1.77)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Length of PICU hospitalisation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 (3&#x02013;7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.65 (4.99)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 (4&#x02013;8)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.47 (4.64)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.273</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.81 (0.54&#x02013;1.20)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.76 (0.49&#x02013;1.18)</td></tr></tbody></table><table-wrap-foot><fn><p>aHR, adjusted hazard ratio; cHR, crude hazard ratio; IQR, interquartile range, sd, standard deviation. <sup>1</sup> Length of total (invasive or non-invasive) mechanical ventilation.</p></fn></table-wrap-foot></table-wrap></floats-group></article>